Trial
NCT02167451
Maraviroc as GVHD Prophylaxis in Transplant Recipients
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Children's Hospital Medical Center, Cincinnati
Collaborators
—
Condition
Diagnoses That Require Stem Cell Transplant
Intervention
Maraviroc
Why stopped
slow recruitment and no further drug supply
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-10